骨质疏松症医药联合门诊对患者用药管理及骨骼健康的影响

doi:10.5246/jcps.2026.07.048

中国药学(英文版) ›› 2026, Vol. 35 ›› Issue (7): 666-680.DOI: 10.5246/jcps.2026.07.048

骨质疏松症医药联合门诊对患者用药管理及骨骼健康的影响

胥甜甜¹^,^#, 王欣¹^,^#, 杜浏学², 杨东²^,^*(), 朱美松²^,^*()

^1. 南昌大学第一附属医院药学部，江西南昌 330000
^2. 南昌大学第一附属医院骨科医院，江西南昌 330000

收稿日期:2026-04-16 修回日期:2026-05-18 接受日期:2026-05-23 出版日期:2026-08-06 发布日期:2026-08-06
通讯作者: 杨东, 朱美松

Effects of osteoporosis medicine-pharmacy joint clinic (OMPJC) on patients’ medication management and bone health

Tiantian Xu¹, Xin Wang¹, Liuxue Du², Dong Yang²^,^*(), Meisong Zhu²^,^*()

^1. Department of Pharmacy, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330000, Jiangxi, China
^2. Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330000, Jiangxi, China

Received:2026-04-16 Revised:2026-05-18 Accepted:2026-05-23 Online:2026-08-06 Published:2026-08-06
Contact: Dong Yang, Meisong Zhu
About author:
^# Tiantian Xu and Xin Wang contributed equally to this work.
Supported by:
Clinical Research Cultivation Project of the First Affiliated Hospital of Nanchang University (Grant No. YFYLCYJPY202543)

摘要/Abstract

摘要：

本研究以2025年4月至9月期间在我院骨质疏松症医药联合门诊(OMPJC)接受治疗的248例患者作为研究对象，旨在探究OMPJC的建设、运行模式及初步效果，并为骨质疏松症的标准化防治提供创新实践方案。OMPJC以骨科主任医师和临床药师为核心，提供涵盖“诊断-治疗-康复”的全周期管理。观察指标包括用药规范性(合理用药率、药物不良反应发生率、用药依从性)、骨代谢相关指标(β-CTX、PINP、25(OH)D)及骨健康改善指标(跌倒发生率)。数据采用SPSS 22.0进行统计分析。最终纳入207例患者，平均年龄66.59 ± 10.41岁。干预后，合理用药率达91.78%，药物不良反应发生率为7.24%，未发生严重不良反应。患者用药依从率为86.96%，运动依从率为76.81%。干预6个月后，与基线相比，患者β-CTX和PINP水平显著下降(P < 0.05)，25(OH)D水平显著升高(P < 0.05)。跌倒发生率从干预前的5.3%降至干预后的1.4%。通过多学科协作模式，该OMPJC有效解决了传统诊疗模式中非规范用药管理、诊疗流程分散及患者认知不足等问题，显著提升了用药安全性和有效性，优化了患者的骨代谢指标，并降低了跌倒发生率。该模式为骨质疏松症的标准化防治提供了可复制的实践路径，具有推广价值。

关键词: 骨质疏松症, 骨质疏松症医药联合门诊, 药物治疗, 管理

Abstract:

To systematically evaluate the establishment, operational framework, and preliminary outcomes of the Osteoporosis Medicine-Pharmacy Joint Clinic (OMPJC), this study aimed to develop an innovative and practice-oriented model to advance standardized prevention and management of osteoporosis. A total of 248 patients who attended the OMPJC at our hospital between April and September 2025 were initially enrolled. The joint clinic was structured around a multidisciplinary core team comprising senior orthopedic physicians and clinical pharmacists, delivering integrated, full-cycle care that spans diagnosis, pharmacotherapy optimization, and rehabilitation management. Key outcome measures included indices of medication standardization (rational drug use rate, incidence of adverse drug reactions, and patient adherence), biomarkers of bone metabolism (β-CTX, PINP, and 25(OH)D), and indicators of bone health improvement (fall incidence rate). Statistical analyses were conducted using SPSS version 22.0. Ultimately, 207 patients met the inclusion criteria and completed follow-up, with a mean age of (66.59 ± 10.41) years. Following implementation of the OMPJC intervention, the rational drug use rate increased to 91.78%, while the overall incidence of adverse drug reactions was 7.24%, with no serious adverse events reported. Medication adherence reached 86.96%, and exercise adherence was 76.81%. After 6 months of continuous management, serum levels of β-CTX and PINP were significantly reduced compared with baseline (P < 0.05), whereas 25(OH)D levels increased significantly (P < 0.05). Notably, the fall incidence rate declined from 5.3% prior to intervention to 1.4% after intervention. Through a structured multidisciplinary collaboration model, the OMPJC effectively addressed key limitations of conventional care, including non-standardized medication management, fragmented diagnostic and therapeutic processes, and insufficient patient engagement. The model substantially enhanced medication safety and therapeutic effectiveness, optimized bone metabolic parameters, and reduced fall risk. Collectively, these findings suggested that the OMPJC represented a scalable and reproducible clinical pathway for the standardized prevention and treatment of osteoporosis, with considerable potential for broader implementation.

Key words: Osteoporosis, Osteoporosis medicine-pharmacy joint clinic, Medication, Management

Supporting:

胥甜甜, 王欣, 杜浏学, 杨东, 朱美松. 骨质疏松症医药联合门诊对患者用药管理及骨骼健康的影响[J]. 中国药学(英文版), 2026, 35(7): 666-680.

Tiantian Xu, Xin Wang, Liuxue Du, Dong Yang, Meisong Zhu. Effects of osteoporosis medicine-pharmacy joint clinic (OMPJC) on patients’ medication management and bone health[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(7): 666-680.

图/表 4

Figure 1. Standardized pharmacotherapy management workflow for osteoporosis.

Table 1. Distribution of anti-osteoporotic medication regimens in patients.

Table 2. Summary of Patient MRPs.

Table 3. Changes in bone metabolism markers and 25(OH)D levels in patients before and after intervention (x ± s).

参考文献 19

[1]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and treatment of primary osteoporosis (2022). Chinese General Practice. 2023, 14, 1671–1691.
[2]	Katsoulis, M.; Benetou, V.; Karapetyan, T.; Feskanich, D.; Grodstein, F.; Pettersson-Kymmer, U.; Eriksson, S.; Wilsgaard, T.; Jørgensen, L.; Ahmed, L.A.; Schöttker, B.; Brenner, H.; Bellavia, A.; Wolk, A.; Kubinova, R.; Stegeman, B.; Bobak, M.; Boffetta, P.; Trichopoulou, A. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J. Intern. Med. 2017, 281, 300–310.
[3]	Cosman, F.; de Beur, S.J.; LeBoff, M.S.; Lewiecki, E.M.; Tanner, B.; Randall, S.; Lindsay, R. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos. Int. 2014, 25, 2359–2381.
[4]	Eisman, J.A.; Bogoch, E.R.; Dell, R.; Harrington, J.T.; McKinney, R.E. Jr, McLellan, A.; Mitchell, P.J.; Silverman, S.; Singleton, R.; Siris, E. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J. Bone Miner. Res. 2012, 27, 2039–2046.
[5]	Zheng, J.; Fu, Y. Advancements in sequential and combination treatments for osteoporosis. J. Chin. Pharm. Sci. 2024, 7, 587–596.
[6]	Lee, S.; Glendenning, P.; Inderjeeth, C.A. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos. Int. 2011, 22, 741–753.
[7]	Laird, C.; Benson, H.; Williams, K.A. Pharmacist interventions in osteoporosis management: a systematic review. Osteoporos. Int. 2023, 34, 239–254.
[8]	Nal, M.; Cömert, U.; Öztürk, M.; Bektaş, G. Rational use of medicines in the older adult: the role of trust in the health care system. BMC Geriatr. 2025, 25, 715.
[9]	Manon, S.M.; Phuong, J.M.; Moles, R.J.; Kelly, A.; Center, J.R.; Luckie, K.; White, C.; Carter, S.R. The role of community pharmacists in delivering interventions for osteoporosis: a systematic review. J. Am. Pharm. Assoc. 2022, 62, 1741–1749.e10.
[10]	Jiao, Y.Z.; Mitchell, N.; Marwick, J.; Malik, F. Evaluating the impact and patient experience of a pharmacist-led osteoporosis clinic: a service evaluation. Musculoskelet. Care. 2024, 22, e1936.
[11]	Rizzoli, R.; Reginster, J.Y. Adverse drug reactions to osteoporosis treatments. Expert Rev. Clin. Pharmacol. 2011, 4, 593–604.
[12]	ESCEO; IOF; IFCC. Update on the Role of Bone Turnover Markers in the Diagnosis and Management of Osteoporosis. Osteoporos. Int. 2025, 7, 1489–1506.
[13]	Wu, J.Y.; Wang, C.; Li, G.F.; Tang, E.T.; Zheng, Q.S. Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: a model-based meta-analysis. Br. J. Clin. Pharmacol. 2021, 87, 1175–1186.
[14]	Holick, M.F. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev. Endocr. Metab. Disord. 2017, 18, 153–165.
[15]	Hashimoto, S.; Hosoi, T.; Yakabe, M.; Yunoki, M.; Matsumoto, S.; Kase, Y.; Miyawaki, M.; Ishii, M.; Ogawa, S. Preventative approaches to falls and frailty. Osteoporos. Sarcopenia. 2025, 11, 50–53.
[16]	Hopewell, S.; Adedire, O.; Copsey, B.J.; Boniface, G.J.; Sherrington, C.; Clemson, L.; Close, J.C.; Lamb, S.E. Multifactorial and multiple component interventions for preventing falls in older people living in the community. Cochrane Database Syst. Rev. 2018, 7, CD012221.
[17]	Inderjeeth, C.A.; Inderjeeth, A.J.; Raymond, W.D. Medication selection and patient compliance in the clinical management of osteoporosis. Aust Fam Physician. 2016, 11, 814–817.
[18]	Fernandes, B.D.; Almeida, P.H.R.F.; Foppa, A.A.; Sousa, C.T.; Ayres, L.R.; Chemello, C. Pharmacist-led medication reconciliation at patient discharge: a scoping review. Res. Soc. Adm. Pharm. 2020, 16, 605–613.
[19]	Ahmed, S.; Kung, J.; Chiang, V.; Poudel, A.; Olufemi-Yusuf, D.; Faruquee, C.F.; Makowsky, M.; Nissen, L.; Guirguis, L. Mapping the U.S. literature on pharmacists prescribing to initiate medications: a scoping review of terminology, responsibilities, and alignment with international models. J. Am. Pharm. Assoc. 2026, 66, 102952.

骨质疏松症医药联合门诊对患者用药管理及骨骼健康的影响

Effects of osteoporosis medicine-pharmacy joint clinic (OMPJC) on patients’ medication management and bone health

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

[1]	林硕, 陈晶晶, 鞠建杰, 袁忠勇, 王周华. 肾移植术后感染与免疫抑制治疗[J]. 中国药学(英文版), 2026, 35(5): 467-480.
[2]	余馨, 冯欣, 安卓玲, 杨辉. 他克莫司相关胃肠道溃疡: 一项观察性、回顾性、药物警戒研究[J]. 中国药学(英文版), 2025, 34(9): 873-881.
[3]	余馨, 王欣蕊, 安卓玲, 冯欣, 杨辉. 一项关于钙调磷酸酶抑制剂相关心脏损害的药物警戒研究: 特别关注心室肥厚[J]. 中国药学(英文版), 2025, 34(8): 732-740.
[4]	王媛, 王珣. 高校大型仪器技术平台实验技术队伍的建设初探——以北京大学药学院为例[J]. 中国药学(英文版), 2025, 34(4): 392-399.
[5]	温雨馨, 蒋琪, 黄壮, 陈鹏宇, 洪星, 汪琼, 黄韬, 韩林涛. 股骨组织的代谢组学分析揭示知母对骨质疏松大鼠代谢途径的影响[J]. 中国药学(英文版), 2025, 34(2): 135-149.
[6]	杨东升, 牛剑钊, 冯玉飞, 刘年, 马玲云. 含亚硝胺杂质的药品对我国仿制药参比制剂可及性的影响[J]. 中国药学(英文版), 2025, 34(1): 75-81.
[7]	郑佳, 付颖. 骨质疏松症中联合和序贯治疗的进展[J]. 中国药学(英文版), 2024, 33(7): 587-596.
[8]	耿魁魁, 何娟, 戎生, 贾兆虎, 张香香, 史天陆. 基于失效模式与效应分析我院PIVAS开展非整支用量药品调配全流程风险管理实践[J]. 中国药学(英文版), 2024, 33(7): 597-608.
[9]	袁叶, 杨珍珍, 于博, 杨秀岭. 1例合并附壁血栓的缺血性心肌病心衰患者的用药分析及药学服务[J]. 中国药学(英文版), 2024, 33(1): 63-68.
[10]	牛剑钊, 杨东升, 冯玉飞, 孙百浩, 关皓月, 马玲云. 药品中亚硝胺类杂质介绍[J]. 中国药学(英文版), 2023, 32(3): 223-230.
[11]	王昌, 江琛, 陈敬, 张程亮. 美国阿片危机及其应对策略[J]. 中国药学(英文版), 2023, 32(2): 122-129.
[12]	杨杰, 孟海阳, 李朵璐, 王艳英, 古兆森, 张晓坚. 国内中西医结合病房的药物治疗相关问题研究[J]. 中国药学(英文版), 2022, 31(4): 279-288.
[13]	冯书云, 陈朋举, 王宁, 赵博, 卢奕帆, 张永恒. 老年慢性病患者合作药物治疗管理模式的探索[J]. 中国药学(英文版), 2022, 31(11): 866-876.
[14]	刘玥华, 薛章勤, 魏剑明, 魏若梦, 殷宝栋, 刘爱芹. 奥帕膦酸钠的药物合成及活性研究[J]. 中国药学(英文版), 2022, 31(11): 883-892.
[15]	吴钰珊, 阳丽梅, 黄旭慧, 黄烽, 韩涛. CYP2C9*3和CYP4F2 rs2108622基因多态性对中国华法林治疗患者过度抗凝和出血并发症的影响: 一项队列研究[J]. 中国药学(英文版), 2021, 30(6): 484-494.